Full View

Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia …

RB Walter, KM Boyle, FR Appelbaum… - Blood, The Journal …, 2008 - ashpublications.org
Targeting CD33 or CD45 is currently exploited for immunotherapy of acute myeloid
leukemia (AML). Gemtuzumab ozogamicin (GO), an immunoconjugate of an anti-CD33 …
被引用次数：23 相关文章

Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia …

RB Walter, KM Boyle, FR Appelbaum… - …, 2008 - pubmed.ncbi.nlm.nih.gov
Targeting CD33 or CD45 is currently exploited for immunotherapy of acute myeloid
leukemia (AML). Gemtuzumab ozogamicin (GO), an immunoconjugate of an anti-CD33 …
[HTML] sciencedirect.com

[HTML][HTML] Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid …

RB Walter, KM Boyle, FR Appelbaum, ID Bernstein… - Blood, 2008 - Elsevier
Targeting CD33 or CD45 is currently exploited for immunotherapy of acute myeloid
leukemia (AML). Gemtuzumab ozogamicin (GO), an immunoconjugate of an anti-CD33 …

[引用][C] Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid …

RB WALTER, KM BOYLE, FR APPELBAUM… - Blood, 2008 - pascal-francis.inist.fr
Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33
immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and …
[HTML] nih.gov

[HTML][HTML] Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid …

RB Walter, KM Boyle, FR Appelbaum, ID Bernstein… - Blood, 2008 - ncbi.nlm.nih.gov
Targeting CD33 or CD45 is currently exploited for immunotherapy of acute myeloid
leukemia (AML). Gemtuzumab ozogamicin (GO), an immunoconjugate of an anti-CD33 …
[PDF] psu.edu

[PDF][PDF] Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid …

RB Walter, KM Boyle, FR Appelbaum, ID Bernstein… - Blood, 2008 - Citeseer
CD33 and CD45 are currently exploited for immunotherapy of acute myeloid leukemia
(AML). 1, 2 The recognition that CD33 is found on most AML blasts led to the development …

[引用][C] Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, Gemtuzumab ozogamicin, against acute myeloid …

RB Walter, KM Boyle, FR Appelbaum… - …, 2008 - providence.elsevierpure.com
Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33
immunoconjugate, Gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and …

Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia …

RB Walter, KM Boyle, FR Appelbaum, ID Bernstein… - Blood, 2008 - europepmc.org
Targeting CD33 or CD45 is currently exploited for immunotherapy of acute myeloid
leukemia (AML). Gemtuzumab ozogamicin (GO), an immunoconjugate of an anti-CD33 …

Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia …

RB Walter, KM Boyle, FR Appelbaum, ID Bernstein… - Blood, 2008 - europepmc.org
Targeting CD33 or CD45 is currently exploited for immunotherapy of acute myeloid
leukemia (AML). Gemtuzumab ozogamicin (GO), an immunoconjugate of an anti-CD33 …